Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD

Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD

Sodium glucose cotransporter-2 inhibitors (SGLT2is) are now widely used to treat diabetes, but their effects on nonalcoholic fatty liver disease (NAFLD) remain to be determined. We aimed to evaluate the effects of SGLT2is on the pathogenesis of NAFLD. A multicenter, randomized, controlled trial was...

Full description

Saved in:
Bibliographic Details
Main Authors: Hirokazu Takahashi, Takaomi Kessoku, Miwa Kawanaka, Michihiro Nonaka, Hideyuki Hyogo, Hideki Fujii, Tomoaki Nakajima, Kento Imajo, Kenichi Tanaka, Yoshihito Kubotsu, Hiroshi Isoda, Satoshi Oeda, Osamu Kurai, Masato Yoneda, Masafumi Ono, Yoichiro Kitajima, Ryo Tajiri, Ayako Takamori, Atsushi Kawaguchi, Shinichi Aishima, Masayoshi Kage, Atsushi Nakajima, Yuichiro Eguchi, Keizo Anzai
Format: Article
Language:English
Published: Endocrinology Research Centre 2025-05-01
Series:Сахарный диабет
Subjects:
sodium glucose cotransporter-2 inhibitor
nonalcoholic fatty liver disease
type 2 diabetes
ipragliflozin
Online Access:https://www.dia-endojournals.ru/jour/article/view/13340
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dia-endojournals.ru/jour/article/view/13340

Similar Items